Mederi Therapeutics has announced two milestones for its Stretta Therapy, a treatment for gastroesophageal reflux disease.
Stretta has now been used for the treatment of GERD in 18,000 cases. The therapy has also received new regulatory approval in the Australia, Argentina, India, Mexico, South Africa and South Korea markets. Mederi Therapeutics also expects to receive regulatory approval in China.
In 2015, the company hopes to gain approval in Brazil, Cost Rica, Egypt, Panama and more.
"It's rewarding to witness worldwide appreciation of how Stretta offers relief to patients with chronic GERD. More than 37 studies from five continents have clearly documented that Stretta is effective and safe, with the lowest reported complication rate of any non-drug option for GERD," said Mark Noar, MD, director of the Heartburn and Reflux Study Center in Towson, Md.